Lexicon Pharmaceuticals described the structure-activity relationship of LX1031 as potential treatments for irritable bowel syndrome.
Archives
1. ABBOTT TO REDUCE COST OF ANTIRETROVIRAL KALETRA BY 30 2. AS TEMPERATURES HEAT UP BEWARE OF HEAT RELATED ILLNESSES
3. BETTER BRUSHING HABITS BOOST EUROPEAN ORAL CARE SALES
4. DRUGS IMPAIR SELF CONTROL IN ADDICTS
5. DSHS ISSUES FLOOD RELATED HEALTH PRECAUTIONS
6. ELI LILLY PROGRAM TO HELP STATES MONITOR PSYCHIATRIC PRESCRIPTIONS EXAMINED
7. FDA APPROVES FIRST GENERIC VERSIONS OF LAMISIL TABLETS
8. FDA APPROVES MARKET GENERIC VERSION OF PAXIL
9. FDA REJECTS MORE NEW MEDICATIONS THIS YEAR THAN IN 2006
10. HAWAII CONSUMERS WARNED ABOUT COLGATE TOOTHPASTE
11. HEALTH AND SAFETY RECOMMENDATIONS IN RESPONSE TO FLOODING
12. HOW PEOPLE REACT TO DIRECT TO CONSUMER DRUG ADS
13. ILINOIS DEPARTMENT OF HEALTH ENCOURAGES SAFE FOOD HANDLING SWIMMING SAFETY WEST NILE VIRUS PREV
14. LX1031 INVESTIGATIONAL DRUG TREATS IRRITABLE BOWEL SYNDROME
15. MEDICAID PANEL MEMBERS REQUIRED TO DISCLOSE TIES TO PHARMACEUTICAL COMPANIES
16. OPTIMAL DRUG DOSE OF COMMON ANTICOAGULANT
17. OUTDOOR INJURY PREVENTION STARTS IN YOUR OWN BACK YARD
18. SENIORS WITH DRUG COVERAGE SIGNIFICANTLY INCREASED UNDER MEDICARE PART D
19. SUPERGEN REPORTS DOSING OF FIRST PATIENT IN PHASE I TRIAL OF NOVEL TYROSINE KINASE INHIBITOR
20. WATSON RECEIVES FDA APPROVAL FOR GENERIC DURAGESIC